Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/116119
Citations
Scopus Web of Science® Altmetric
?
?
Type: Conference item
Title: Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous NSCLC.
Author: Ramalingam, S.S.
Shtivelband, M.
Soo, R.A.
Barrios, C.H.
Makhson, A.
Segalla, J.
Pittman, K.B.
Kolman, P.
Pereira, J.R.
Srkalovic, G.
Belani, C.P.
Axelrod, R.
Owonikoko, T.K.
Qian, J.
Mckee, M.D.
Ricker, J.L.
Carlson, D.M.
Gorbunova, V.A.
Citation: Journal of Clinical Oncology, 2012, vol.30, iss.15
Publisher: AMER SOC CLINICAL ONCOLOGY
Issue Date: 2012
ISSN: 0732-183X
1527-7755
Conference Name: 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) (1 Jun 2012 - 6 Jun 2012 : Chicago, IL)
Statement of
Responsibility: 
Suresh S. Ramalingam, Mikhail Shtivelband, Ross A. Soo, Carlos H. Barrios, Anatoly Makhson, José G.M. Segalla, Kenneth B. Pittman, Petr Kolman, Jose R. Pereira, Gordan Srkalovic, Chandra P. Belani, Rita Axelrod, Taofeek K. Owonikoko, Qin Qin, Jiang Qian, Evelyn M. McKeegan, Viswanath Devanarayan, Mark D. McKee, Justin L. Ricker, Dawn M. Carlson, Vera A. Gorbunova
Abstract: Purpose: Linifanib, a potent, selective inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors, has single-agent activity in non–small-cell lung cancer (NSCLC). We evaluated linifanib with carboplatin and paclitaxel as first-line therapy of advanced nonsquamous NSCLC. Patients and Methods: Patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned to 3-week cycles of carboplatin (area under the curve 6) and paclitaxel (200 mg/m2) with daily placebo (arm A), linifanib 7.5 mg (arm B), or linifanib 12.5 mg (arm C). The primary end point was progression-free survival (PFS); secondary efficacy end points included overall survival (OS) and objective response rate. Results: One hundred thirty-eight patients were randomly assigned (median age, 61 years; 57% men; 84% smokers). Median PFS times were 5.4 months (95% CI, 4.2 to 5.7 months) in arm A (n = 47), 8.3 months (95% CI, 4.2 to 10.8 months) in arm B (n = 44), and 7.3 months (95% CI, 4.6 to 10.8 months) in arm C (n = 47). Hazard ratios (HRs) for PFS were 0.51 for arm B versus A (P = .022) and 0.64 for arm C versus A (P = .118). Median OS times were 11.3, 11.4, and 13.0 months in arms A, B, and C, respectively. HRs for OS were 1.08 for arm B versus A (P = .779) and 0.88 for arm C versus A (P = .650). Both linifanib doses were associated with increased toxicity, including a higher incidence of adverse events known to be associated with VEGF/PDGF inhibition. Baseline plasma carcinoembryonic antigen/cytokeratin 19 fragments biomarker signature was associated with PFS improvement and a trend toward OS improvement with linifanib 12.5 mg. Conclusion: Addition of linifanib to chemotherapy significantly improved PFS (arm B), with a modest trend for survival benefit (arm C) and increased toxicity reflective of known VEGF/PDGF inhibitory effects.
Keywords: Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Paclitaxel; Carboplatin; Phenylurea Compounds; Indazoles; Receptors, Platelet-Derived Growth Factor; Vascular Endothelial Growth Factor A; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Treatment Outcome; Administration, Oral; Drug Administration Schedule; Adult; Aged; Middle Aged; Female; Male; Kaplan-Meier Estimate
Rights: © 2015 by American Society of Clinical Oncology. All rights reserved.
DOI: 10.1200/JCO.2014.55.7173
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.